Chris Owens

Chris Owens

Sr. Manager, Pharmaceutical Asset Search & Evaluation - PhD

Chris is a Sr. Manager of Pharmaceutical Asset Search & Evaluation supporting a range of partnering and business development assignments.

Professional Background

Chris is a Sr. Manager of Pharmaceutical Asset Search & Evaluation supporting a range of partnering and business development assignments. His experiences include technology and market assessment, competitive landscape analysis, and identification of strategic alliances for biotech and pharma to facilitate in-licensing and out-licensing of various technologies. Prior to Alacrita, Chris has 13 years of experience building and leading teams of scientists in activities supporting target identification, cell-based and biochemical assay development, compound and CRISPR screening, and lead identification and optimization that led to INDs and Phase 1 clinical trials for three separate small molecule drug programs.

Chris has a Ph.D. in Microbiology & Molecular Genetics from Harvard University, an M.M.Sc. (an education encompassing the first two years of Medical School) from Harvard Medical School, and a B.A. in Biochemistry from Knox College. While at Harvard University, he co-discovered TRIM5α in rhesus macaques as a potent post-entry inhibitor of HIV infection. Over the years, he has been listed as an inventor on three patent applications, authored eight peer-reviewed publications in leading medical journals, and given fifteen conference presentations to top scientists in his field.

Current Projects

Chris is currently conducting asset search and evaluation for several clients focused on fibrosis, oncology, NASH, Parkinson’s, and infectious disease therapeutic areas. His duties include identifying potential industry partners, supporting US scouting efforts to identify early stage assets for in-licensing, mapping key company contacts, preparing consulting proposals, and attending partnering and scientific conferences to solicit partnering interest.

Chris also supports the US scouting efforts of a well-capitalized private mid-size pharma seeking new collaboration opportunities in oncology, and/or bacterial infections in the US. In this role he identifies early stage in-licensing, co-development, or acquisition opportunities. The work involves regular attendance at meetings and conferences in Boston and the surrounding area which are likely to attract new early stage biotech companies, including investor meetings or presentations about non-dilutive financing, networking with tech transfer offices, industry contacts and licensing professionals, scanning of new and recent literature to identify emerging opportunities, and searches of multiple online databases. Chris also contacts companies that fit the search criteria to ascertain their interest in a partnership.

Education

  • Harvard University, Ph.D. in Microbiology & Molecular Genetics
  • Harvard Medical School, M.M.Sc. in Medical Science
  • Knox College, B.A. in Biochemistry

PATENTS

  • Or YS, Owens, CM, Brasher B, Qiu Y-L, Jiang L. (2015) (Patent 9,060,971) COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION.
  • Sodroski J, Stremlau M, and Owens CM. (2012) (Patent 8,309,697) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5α.
  • Johansen LM, Owens CM, Mawhiney C, Chappell TW, Brown AT, Frank MG, Altmeyer R. (2008) (PCT/US2007/019932) COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES.

PUBLICATIONS

  • Owens CM, Brasher BB, Polemeropoulos A, Rhodin MHJ, McAllister N, Wong KA, Jones CT, Jiang L-J, Lin K, Or YS (2016) Preclinical and Clinical Resistance Profile of EDP-239, a Novel HCV NS5A Inhibitor. Antimicrobial Agents and Chemotherapy, 60(10):6216-26.
  •  Owens CM, Brasher BB, Polemeropoulos A, Rhodin MHJ, McAllister N, Peng X, Wang C, Ying L, Cao H, Lawitz E, Poordad F, Rondon J, Box TD, Zeuzem S, Buggisch P, Lin K, Qiu Y-L, Jiang L-J, Colvin R, Or YS (2016) Preclinical Profile and Clinical Efficacy of a Novel HCV NS5A Inhibitor, EDP-239. Antimicrobial Agents and Chemotherapy, 60(10):6207-15.
  • Owens CM, Mawhinney C, Grenier J, Altmeyer R, Lee MS, Borisy AA, Lehár J, Johansen LM (2010) Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication. Molecular Systems Biology, 6:375.
  • Choe H, Moore MJ, Owens CM, Wright PL, Vasilieva N, Li W, Singh AP, Shakri R, Chitnis CE, Farzan M. (2005) Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol Microbiol, 55(5):1413-22.
  • Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. (2004) A cytoplasmic body component, TRIM5alpha, restricts human immunodeficiency virus (HIV-1) infection in Old World monkeys. Nature, 427(6977):848-53.
  • Owens CM, Song B, Perron MJ, Yang PC, Stremlau M, Sodroski J. (2004). Binding and susceptibility to post-entry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. J Virol, 78(10):5423-37.
  •  Si Z, Gorry P, Babcock G, Owens CM, Cayabyab M, Phan N, and Sodroski J. (2004) Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys. AIDS Res Hum Retroviruses, 20(2):163-73.
BACK